Early study holds promise for novel treatment in brain cancer
While this is only an early study (Phase I) with a very small number of patients, I think it holds great promise in the treatment of brain cancer. The whole concept of immunomodulatory therapy to stimulate the body’s natural defenses is an interesting research path.
Vaccination therapy may in the future turn out to be another tool to treat brain cancer.
Vaccination therapy may in the future turn out to be another tool to treat
brain cancer, one of the most aggressive types of cancer. It's important
to understand that a Phase I study sets out to determine only if a treatment
is feasible and safe. It is too early to know if this form of therapy will
ever be widely used to treat glioblastoma.
It supports the hypothesis, however, that a person's immune
system can be modulated in order to fight brain cancer, which is
very important news for cancer doctors.
Brain cancer flies under the body's radar
It's
always best when the body's immune system recognizes
cancer cells. However, brain cancer cells often fly under the radar.
The body fails to recognize them. We don't understand why.
We have a very efficient immune system, but for some reason in
patients who develop cancer, it doesn't effectively screen
out cancerous cells, especially in the brain.
We think that cancer cells don't express the types of characteristics
that are picked up by the immune system. We also know that some
cancer cells are better at attracting immune cells; studying the
mechanisms of immune response in those may help explain why this
is not the case in brain cancer.
Vaccine works like any immunization
In very
simple terms, vaccine therapy for cancer treatment works on the
same concept as immunizations for chicken pox, whooping cough and
other bacterial and viral diseases. The vaccine helps to modify
the immune system to recognize brain cancer and to stop it.
The vaccine helps to modify the immune system to recognize brain cancer and to stop it.
In the study, brain tumor cells were exposed to healthy immune cells
in a petri dish in the laboratory. This exposure helped train the
immune cells to better learn to recognize the cancer cells.
Vaccine therapy years away
Although the study
is far from making the vaccine available soon, it does teach us
several things. First, we know that vaccine therapy can be done.
Patients tolerate it well with few side effects. We also know that
it is complex, requires individual tailoring to each patient and
can only be done in very specialized research centers.
I think that this type of therapy should be studied on a larger
scale because results are very promising.
Studies underway
At the Yale Brain Tumor Center, studies are underway that make use of other mechanisms of the
body's immune system. One
study is evaluating the use of a genetically engineered protein
to fight brain cancer.
In a very simple explanation, here is what happens: a protein
called interleukin 13 is combined with a bacterial toxin. When
administered into brain tissue surrounding the tumor through catheters
placed at the time of surgery, the molecule selectively targets
brain cancer cells. The protein is attracted to a cancer cell
and once it is received, it releases the bacterial toxin that kills
the cancer cell.
Early results (Phase I) proved that the treatment is feasible
and is well tolerated. A larger trial (Phase III) comparing the
new treatment with an established one is now underway. Results
are promising and should let patients know that tomorrow holds
more hope for better treatment.
Advice for brain cancer patients
My advice to
patients suffering from brain cancer, and their families, is to
understand the treatment offered to them as best as they can and
research their options.
First, ask what standard or investigational treatment your doctor
or hospital may have available. Find out what novel treatments
may be in use and what medical centers within your reach offer
them. Many promising new treatment approaches are underway in clinical
trials all over the world. Much information on brain tumor treatment
and research is available on the Web.
Dr. Baehring is an attending physician at Yale-New Haven Hospital and assistant professor of neurology and neurosurgery at Yale School of Medicine. He is part of the team at the Yale
Brain Tumor Center and is certified by the American Board of Psychiatry and Neurology.